Prevent the Preventable

Senzime develops and markets unique CE- and FDA-approved medical device solutions, driven by unique algorithms and sensors for bedside monitoring of anesthesia. TetraGraph® is a system that measures the level of neuromuscular blockade digitally and continuously to prevent complications, improve clinical precision and simplify management of care. TetraGraph® helps prevent complications and enables health care staff to comply with guidelines and drug recommendations, thus helping shorten hospitalizations and cut health care costs. Senzime’s vision is a world without anesthesiarelated complications, and safe emergence from anesthesia for all patients. Senzime operates on expansive markets worth in excess of SEK 10 billion in Europe and the US alone.

Senzime´s innovative device, TetraGraph, supports the optimization of patient management in patients receiving neuromuscular blocking agents (NMBAs). TetraGraph can be used from start to finish during the surgical procedure. The monitor enables objective assessment of the depth of block and titration of medication dosage to help determine when the patient has recovered sufficiently to maintain spontaneous breathing.

The Senzime AB (publ) share are listed on NASDAQ Stockholm First North Growth Market. Short name: SEZI.

Senzime AB is located in Uppsala, Sweden.

Residual Neuromuscular Blockade

Qualitative vs Quantitative Monitorin

EMG

The new Gold Standard

Press releases

Senzime’s Interim report January – September 2020

Read more

Nomination Committee in Senzime ahead of the 2021 Annual General Meeting

Read more

Senzime out-licenses OnZurf Probe on the European market

Read more
See all »

News

Task Force developing European Guidelines for Neuromuscular Blockade Management

Read more

Senzime invitation to new website

Read more

Senzime Joins the Anesthesia Patient Safety Foundation (APSF) as a member of the Corporate Advisory Counsel

Read more
See all »